248 related articles for article (PubMed ID: 36681680)
1. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.
Nassar AH; Abou Alaiwi S; Baca SC; Adib E; Corona RI; Seo JH; Fonseca MAS; Spisak S; El Zarif T; Tisza V; Braun DA; Du H; He M; Flaifel A; Alchoueiry M; Denize T; Matar SG; Acosta A; Shukla S; Hou Y; Steinharter J; Bouchard G; Berchuck JE; O'Connor E; Bell C; Nuzzo PV; Mary Lee GS; Signoretti S; Hirsch MS; Pomerantz M; Henske E; Gusev A; Lawrenson K; Choueiri TK; Kwiatkowski DJ; Freedman ML
Nat Commun; 2023 Jan; 14(1):346. PubMed ID: 36681680
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
3. Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms.
Skala SL; Wang X; Zhang Y; Mannan R; Wang L; Narayanan SP; Vats P; Su F; Chen J; Cao X; Siddiqui J; Argani P; Cieślik MP; Giordano TJ; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Eur Urol; 2020 Jul; 78(1):63-74. PubMed ID: 32299640
[TBL] [Abstract][Full Text] [Related]
4. Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types.
Wang X; Kong W; Wang Y; Wang Y; Chen Y; Shi Z; Liu Y
J BUON; 2021; 26(5):2053-2058. PubMed ID: 34761616
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
6. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
Zhao H; Leppert JT; Peehl DM
PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
[TBL] [Abstract][Full Text] [Related]
7. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
[TBL] [Abstract][Full Text] [Related]
8. FOXI1 expression in chromophobe renal cell carcinoma and renal oncocytoma: a study of The Cancer Genome Atlas transcriptome-based outlier mining and immunohistochemistry.
Tong K; Hu Z
Virchows Arch; 2021 Apr; 478(4):647-658. PubMed ID: 32812119
[TBL] [Abstract][Full Text] [Related]
9. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
10. Expression and clinical value of SALL4 in renal cell carcinomas.
Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
[TBL] [Abstract][Full Text] [Related]
11. Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma.
Siebenthall KT; Miller CP; Vierstra JD; Mathieu J; Tretiakova M; Reynolds A; Sandstrom R; Rynes E; Haugen E; Johnson A; Nelson J; Bates D; Diegel M; Dunn D; Frerker M; Buckley M; Kaul R; Zheng Y; Himmelfarb J; Ruohola-Baker H; Akilesh S
EBioMedicine; 2019 Mar; 41():427-442. PubMed ID: 30827930
[TBL] [Abstract][Full Text] [Related]
12. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
15. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
16. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
17. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
18. [Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis].
Wang Y; Hou MY; Fu Y; Meng K; Wu HY; Chen J; Xu YM; Shi J; Fan XS
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):358-363. PubMed ID: 36973196
[No Abstract] [Full Text] [Related]
19. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
[TBL] [Abstract][Full Text] [Related]
20. KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms.
Petit A; Castillo M; Santos M; Mellado B; Alcover JB; Mallofré C
Am J Surg Pathol; 2004 May; 28(5):676-8. PubMed ID: 15105658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
